iCare HOME2 Clinical Trial

Sponsor
Icare Finland Oy (Industry)
Overall Status
Completed
CT.gov ID
NCT05162989
Collaborator
(none)
47
1
1
19
75.3

Study Details

Study Description

Brief Summary

The aim of this clinical study is to provide information about the variability of the intraocular pressure (IOP) self-measurements with the iCare HOME2 tonometer in comparison to the variability of the IOP measurements with the reference tonometer (iCare IC200), over a wide range of IOP values.

Condition or Disease Intervention/Treatment Phase
  • Device: iCare HOME2 vs iCare IC200
N/A

Detailed Description

The clinical study is planned to estimate the variability of the IOP measurement of iCare HOME2 and IC200. In the study, the subjects will learn to operate the iCare HOME2 tonometer independently by using the labeling materials provided to them. Once they learn to operate the tonometer, subjects will take three self-measurements on the selected eye both in sitting and supine position.

The variability of the measurement results taken with iCare HOME2 will be compared to the variability of the measurement results taken with iCare IC200 by using the recorded results from the study subjects.

Study Design

Study Type:
Interventional
Actual Enrollment :
47 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
Investigator cannot see both the test device and reference device measurement results.
Primary Purpose:
Diagnostic
Official Title:
iCare HOME2 Clinical Trial
Actual Study Start Date :
Nov 26, 2021
Actual Primary Completion Date :
Dec 15, 2021
Actual Study Completion Date :
Dec 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: iCare HOME2 vs iCare IC200

Measurement of intraocular pressure (IOP) with iCare IC200 reference tonometer compared to iCare HOME2 test tonometer. Measurement will be performed to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).

Device: iCare HOME2 vs iCare IC200
Measurement of IOP with iCare HOME2 compared with iCare IC200.

Outcome Measures

Primary Outcome Measures

  1. Repeatability of IOP measurements [Through study completion, an average of 1-2 months]

    Repeatability of IOP measurements comparison of iCare HOME2 vs iCare IC200

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Glaucoma patients having confirmed optic nerve damage with visual field defects consistent with the glaucomatous optic neuropathy or

  • Glaucoma-suspects being followed because of elevated IOP, and/or because of other risk factors for developing glaucoma or optic nerve damage.

Exclusion Criteria:
  • Active ocular infection (e.g., pink eye or infectious conjunctivitis)

  • Recent trauma to the eye including corneal laceration or corneal/scleral perforation

  • Disabling arthritis or difficulty handling the tonometer

  • Severe difficulty in opening the eyes including abnormal contractions or twitches of the eyelid (blepharospasm)

  • Involuntary, rapid, and repetitive eye movements (nystagmus)

  • Low uncorrected near visual acuity of 20/200 or below

  • Significant glaucomatous central field loss

  • Only one functional eye

  • Poor or off-center visual fixation

  • Poor hearing and/or communicates using sign language

  • Keratoconus (or other corneal disorder)

  • Congenitally small eye (microphthalmos)

  • Enlarged eyeball from the childhood glaucoma (buphthalmos)

  • Previous experience using or interacting with the HOME tonometer during usability tests or clinical trials

  • Any affiliation with Icare and its employees

  • High corneal astigmatism (>3d)

  • History of prior invasive corneal surgery including corneal laser surgery less than six months ago (e.g., LASIK, LASEK, Smile)

  • Corneal scarring

  • Very thick or very thin corneas (central corneal thickness greater than 600 μm or less than 500 μm)

  • Cataract extraction within the last 2 months

  • Wearing contact lenses during the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 East West Eye Institute Los Angeles California United States 90013

Sponsors and Collaborators

  • Icare Finland Oy

Investigators

  • Principal Investigator: Michelle A Sato, MD, East West Eye Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Icare Finland Oy
ClinicalTrials.gov Identifier:
NCT05162989
Other Study ID Numbers:
  • TA023-207
First Posted:
Dec 20, 2021
Last Update Posted:
Dec 20, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 20, 2021